Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study (vol 56, pg 770, 2020)

被引：0
作者：
Zamarin, Dmitriy
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2702 / 2702
页数：1
相关论文
共 50 条
  • [31] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
    Burger, Robert A.
    Sill, Michael W.
    Monk, Bradley J.
    Greer, Benjamin E.
    Sorosky, Joel I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
  • [32] A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
    Jandial, Danielle A.
    Brady, William E.
    Howell, Stephen B.
    Lankes, Heather A.
    Schilder, Russell J.
    Beumer, Jan H.
    Christner, Susan M.
    Strychor, Sandra
    Powell, Matthew A.
    Hagemann, Andrea R.
    Moore, Kathleen N.
    Walker, Joan L.
    DiSilvestro, Paul A.
    Duska, Linda R.
    Fracasso, Paula M.
    Dizon, Don S.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (02) : 236 - 242
  • [33] FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
    Lorenzen, S.
    Thuss-Patience, P. C.
    Folprecht, G.
    Knorrenschild, J. Riera
    Heinemann, V.
    Goekkurt, E.
    Dechow, T. N.
    Ettrich, T. J.
    Luley, K. B.
    Moulin, J. C.
    Lindig, U.
    Angermeier, S.
    Waidmann, O.
    Pink, D.
    Bolling, C.
    Junge, S.
    Pauligk, C.
    Gaiser, T.
    Goetze, T. O.
    Al-Batran, S. E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1099 - S1099
  • [34] Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)
    Chen, Inna M.
    Johansen, Julia S.
    Theile, Susann
    Hjaltelin, Jessica X.
    Novitski, Sif, I
    Brunak, Soren
    Hasselby, Jane P.
    Willemoe, Gro L.
    Lorentzen, Torben
    Madsen, Kasper
    Jensen, Benny, V
    Wilken, Eva E.
    Geertsen, Poul
    Behrens, Claus
    Nolsoe, Christian
    Hermann, Kirstine L.
    Svane, Inge Marie
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) : 3180 - +
  • [35] A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
    Sabbatini, Paul
    Sill, Michael W.
    O'Malley, David
    Adler, Lisa
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2008, 111 (03) : 455 - 460
  • [36] Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
    Aghajanian, Carol
    Sill, Michael W.
    Darcy, Kathleen M.
    Greer, Benjamin
    McMeekin, D. Scott
    Rose, Peter G.
    Rotmensch, Jacob
    Barnes, Mack N.
    Hanjani, Parviz
    Leslie, Kimberly K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2259 - 2265
  • [37] NEOADJUVANT CHEMORADIOTHERAPY WITH SEQUENTIAL IPILIMUMAB AND NIVOLUMAB IN RECTAL CANCER (CHINOREC): A PROSPECTIVE RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II CLINICAL TRIAL
    Laengle, J.
    Kuehrer, I.
    Pils, D.
    Kabiljo, J.
    Woeran, K.
    Stift, J.
    Herbst, F.
    Dauser, B.
    Monschein, M.
    Razek, P.
    Haegele, S.
    Herac, M.
    Hulla, W.
    Bitterman, C.
    Laengle, F.
    Tamandl, D.
    Widder, J.
    Schmid, R.
    Bergmann, M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A51 - A51
  • [38] Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.
    Laengle, Johannes
    Kuehrer, Irene
    Kulu, Askin
    Kabiljo, Julijan
    Ammon, Daphni
    Zirnbauer, Rebecca
    Stift, Anton
    Herbst, Friedrich
    Dauser, Bernhard
    Monschein, Matthias
    Razek, Peter
    Biebl, Matthias
    Geinitz, Hans
    Hulla, Wolfgang
    Muellauer, Leonhard
    Widder, Joachim
    Bittermann, Clemens
    Laengle, Friedrich
    Schmid, Rainer
    Bergmann, Michael M.
    CHINOREC Study Grp
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 139 - 139
  • [39] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
    T. M. L. Tong
    M. K. van der Kooij
    F. M. Speetjens
    A. R. van Erkel
    R. W. van der Meer
    J. Lutjeboer
    E. L. van Persijn van Meerten
    C. H. Martini
    R. W. M. Zoethout
    F. G. J. Tijl
    C. U. Blank
    M. C. Burgmans
    E. Kapiteijn
    Trials, 23
  • [40] Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
    Tong, Thais M. L.
    Burgmans, Mark C.
    Van der Kooij, Monique
    Speetjens, Frank M.
    van Erkel, Arian R.
    van der Meer, Rutger W.
    van den Bosch, Shelley
    Jonker, Mare A.
    Roozen, Inge C. F. M.
    Lutjeboer, Jacob
    Rijksen, Fenna
    van Persijn-van Meerten, Els L.
    Martini, Chris H.
    Zoethout, Remco W. M.
    Tijl, Fred G. J.
    Blank, Christian U.
    Kapiteijn, Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345